Quadrature Capital’s Acrivon Therapeutics ACRV Stock Holding History

Quadrature Capital’s Portfolio ACRV Stock Details ACRV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-20,730	Closed	-$50K	–	1319
2025 Q4	$50K	Buy	+20,730	New	+$45.1K	﹤0.01%	1178
2025 Q3	–	Sell	-22,175	Closed	-$26.3K	–	1002
2025 Q2	$26.3K	Buy	+22,175	New	+$30.4K	﹤0.01%	987

Other funds holding ACRV

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

SCV

Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Quadrature Capital's ACRV Position: Q1 2026 in Review

Quadrature Capital sold out of Acrivon Therapeutics (ACRV) in Q1 2026, closing a stake of 20,730 shares — an estimated $50K sold.

Quadrature Capital first reported a position in ACRV in Q2 2025 and held it in 2 quarters. The position peaked at $50K in Q4 2025. 44 funds tracked by Wall St. Rank hold ACRV as of Q1 2026.

Quadrature Capital reported no remaining Acrivon Therapeutics position as of Q1 2026 after selling out during the quarter.
Quadrature Capital sold 20,730 Acrivon Therapeutics shares in Q1 2026, an estimated $50K.
Quadrature Capital first reported a position in Acrivon Therapeutics in Q2 2025 and held it in 2 quarters.
Quadrature Capital's Acrivon Therapeutics position peaked at $50K in Q4 2025.
44 funds tracked by Wall St. Rank held Acrivon Therapeutics as of Q1 2026.

Based on Quadrature Capital's 13F filing for Q1 2026, filed 15 May 2026.